Latest News -Mito Advocacy
Advocacy Action: Ask Congress to Oppose 57% Cut to Congressionally Directed Medical Research Programs
Updated 3/12/25, 11amLast night, the House approved the continuing resolution — including the 57% CDMRP cut — to fund the...
Read: Advocacy Action: Ask Congress to Oppose 57% Cut to Congressionally Directed Medical Research ProgramsUMDF November Advocacy Update: What Does a Second Trump Administration Mean for the Mito Community?
With the recent election results, we’ve been getting some inquiries about the impact of a second Trump Administration on mitochondrial disease...
Read: UMDF November Advocacy Update: What Does a Second Trump Administration Mean for the Mito Community?UMDF Cosigns Letter to Congress Encouraging End-of-Year Rare Disease Legislative Priorities
UMDF Cosigns Letter to Congress Encouraging End-of-Year Action on Accelerating Kids’ Access to Care Act, Rare Pediatric Disease Priority Review...
Read: UMDF Cosigns Letter to Congress Encouraging End-of-Year Rare Disease Legislative PrioritiesAdvocacy Update – Oct 2024: FDA AdComm Brings Good News, Plus DC End of Year Business
FDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...
Read: Advocacy Update – Oct 2024: FDA AdComm Brings Good News, Plus DC End of Year BusinessUMDF Reacts to FDA Advisory Committee’s Elamipretide Recommendation
After a full day of testimony that consistently demonstrated the need and efficacy of elamipretide for the treatment of Barth Syndrome, an FDA...
Read: UMDF Reacts to FDA Advisory Committee’s Elamipretide Recommendation